Ascendis Pharma A/S (ASND)
A
Pipeline Grade
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
NAVEPEGRITIDE
YUVIWEL |
APPROVED | 2L+ Cervical Cancer, Achondroplasia, Adult Growth Hormone Deficiency, Advanced Solid Tumor, Endocrine System Diseases, Growth Hormone Deficiency (GHD), Growth Hormone Deficiency, Pediatric, Growth Hormone-Deficiency, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma HNSCC, Healthy, Healthy Volunteers, hGH (Human Growth Hormone), Hormone Deficiency, Hormones, HPV-associated Cancers, Hypoparathyroidism, Idiopathic Short Stature, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC), Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Parathyroid Diseases, Pituitary Disease, Anterior, Pituitary Diseases, Platinum-resistant Ovarian Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Post Anti-PD-1 Melanoma, Second or Third Line (2L/3L) Cervical Cancer, Short Stature Homeobox Gene Mutation, Small for Gestational Age at Delivery, Third Line or Later (3L+) HER2+ Breast Cancer, Third-line or Later ( |
Upcoming Catalysts
No upcoming catalysts detected for this company.